Profile of plasma microRNAs as a potential biomarker of Wilson's disease.
Por:
Sánchez-Monteagudo A, Ripollés E, Murillo O, Domènech S, Álvarez-Sauco M, Girona E, Sastre-Bataller I, Bono A, García-Villarreal L, Tugores A, García-García F, González-Aseguinolaza G, Berenguer M and Espinós C
Publicada:
26 jul 2024
Ahead of Print:
26 jul 2024
Resumen:
Wilson's disease (WD) is a rare condition resulting from autosomal recessive mutations in ATP7B, a copper transporter, manifesting with hepatic, neurological, and psychiatric symptoms. Timely diagnosis and appropriate treatment yield a positive prognosis, while delayed identification and/or insufficient therapy lead to a poor outcome. Our aim was to establish a prognostic method for WD by characterising biomarkers based on circulating microRNAs.
Filiaciones:
Sánchez-Monteagudo A:
Unit of Rare Neurodegenerative Diseases, Valencia Biomedical Research Foundation-Centro de Investigación Príncipe Felipe (CIPF), Calle Eduardo Primo Yúfera No. 13, 46012, Valencia, Spain
Ripollés E:
Unit of Rare Neurodegenerative Diseases, Valencia Biomedical Research Foundation-Centro de Investigación Príncipe Felipe (CIPF), Calle Eduardo Primo Yúfera No. 13, 46012, Valencia, Spain
Rare Diseases Joint Unit, CIPF-IIS La Fe, Valencia, Spain
Murillo O:
DNA@RNA Medicine Division, Centro de Investigación Médica Aplicada (CIMA), University of Navarra, Pamplona, Spain
Domènech S:
Unit of Rare Neurodegenerative Diseases, Valencia Biomedical Research Foundation-Centro de Investigación Príncipe Felipe (CIPF), Calle Eduardo Primo Yúfera No. 13, 46012, Valencia, Spain
Rare Diseases Joint Unit, CIPF-IIS La Fe, Valencia, Spain
Álvarez-Sauco M:
Department of Neurology, Hospital General Universitari d'Elx, Alicante, Spain
Girona E:
Department of Internal Medicine, Hospital General Universitari d'Elx, Alicante, Spain
Sastre-Bataller I:
Rare Diseases Joint Unit, CIPF-IIS La Fe, Valencia, Spain
Department of Neurology, Hospital Universitari I Politècnic La Fe, Valencia, Spain
Bono A:
Rare Diseases Joint Unit, CIPF-IIS La Fe, Valencia, Spain
Hepatology-Liver Transplantation Unit, Digestive Medicine Service, IIS La Fe and CIBER-EHD, Hospital Universitari i Politècnic La Fe, Valencia, Spain
García-Villarreal L:
Research Unit, Complejo Hospitalario Universitario Insular Materno-Infantil, Las Palmas de Gran Canaria, Spain
Tugores A:
Research Unit, Complejo Hospitalario Universitario Insular Materno-Infantil, Las Palmas de Gran Canaria, Spain
García-García F:
Rare Diseases Joint Unit, CIPF-IIS La Fe, Valencia, Spain
Unit of Bioinformatics and Biostatistics, Valencia Biomedical Research Foundation-Centro de Investigación Príncipe Felipe (CIPF), Valencia, Spain
González-Aseguinolaza G:
DNA@RNA Medicine Division, Centro de Investigación Médica Aplicada (CIMA), University of Navarra, Pamplona, Spain
Vivet Therapeutics S.L., Pamplona, Spain
Berenguer M:
Rare Diseases Joint Unit, CIPF-IIS La Fe, Valencia, Spain
Hepatology-Liver Transplantation Unit, Digestive Medicine Service, IIS La Fe and CIBER-EHD, Hospital Universitari i Politècnic La Fe, Valencia, Spain
Department of Medicine, Universitat de València, Valencia, Spain
:
Unit of Rare Neurodegenerative Diseases, Valencia Biomedical Research Foundation-Centro de Investigación Príncipe Felipe (CIPF), Calle Eduardo Primo Yúfera No. 13, 46012, Valencia, Spain.
Rare Diseases Joint Unit, CIPF-IIS La Fe, Valencia, Spain.
Biotechnology Department, Universitat Politècnica de València, Valencia, Spain.
Rare Diseases Networking Biomedical Research Centre (CIBERER), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.
hybrid
|